You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an alternative browser.
You should upgrade or use an alternative browser.
drug study combining the two VX drugs
- Thread starter Jeana
- Start date
looks like the interaction study was done
<a target=_blank class=ftalternatingbarlinklarge href="http://clinicaltrials.gov/ct2/show/NCT00966602
">http://clinicaltrials.gov/ct2/show/NCT00966602
</a>
From an earlier press release, it sounds like later this year
<a target=_blank class=ftalternatingbarlinklarge href="http://www.drugs.com/clinical_trials/vertex-announces-results-phase-2a-trial-vx-809-targeting-defective-protein-responsible-cystic-8824.html
">http://www.drugs.com/clinical_...ible-cystic-8824.html
</a>
"Based on the Phase 2 data announced today, Vertex plans to initiate a combination trial of VX-809 with the CFTR potentiator VX-770 in patients with the most common CFTR mutation, F508del, in the second half of 2010. In in vitro studies, a combination regimen of VX-770 and VX-809 has been shown to increase CFTR activity when compared to dosing of VX-770 or VX-809 as single agents. In addition, Vertex is conducting further analyses of the Phase 2a data and may explore the option to evaluate VX-809 doses of greater than 200 mg when dosed as a single agent".
<a target=_blank class=ftalternatingbarlinklarge href="http://clinicaltrials.gov/ct2/show/NCT00966602
">http://clinicaltrials.gov/ct2/show/NCT00966602
</a>
From an earlier press release, it sounds like later this year
<a target=_blank class=ftalternatingbarlinklarge href="http://www.drugs.com/clinical_trials/vertex-announces-results-phase-2a-trial-vx-809-targeting-defective-protein-responsible-cystic-8824.html
">http://www.drugs.com/clinical_...ible-cystic-8824.html
</a>
"Based on the Phase 2 data announced today, Vertex plans to initiate a combination trial of VX-809 with the CFTR potentiator VX-770 in patients with the most common CFTR mutation, F508del, in the second half of 2010. In in vitro studies, a combination regimen of VX-770 and VX-809 has been shown to increase CFTR activity when compared to dosing of VX-770 or VX-809 as single agents. In addition, Vertex is conducting further analyses of the Phase 2a data and may explore the option to evaluate VX-809 doses of greater than 200 mg when dosed as a single agent".
looks like the interaction study was done
<a target=_blank class=ftalternatingbarlinklarge href="http://clinicaltrials.gov/ct2/show/NCT00966602
">http://clinicaltrials.gov/ct2/show/NCT00966602
</a>
From an earlier press release, it sounds like later this year
<a target=_blank class=ftalternatingbarlinklarge href="http://www.drugs.com/clinical_trials/vertex-announces-results-phase-2a-trial-vx-809-targeting-defective-protein-responsible-cystic-8824.html
">http://www.drugs.com/clinical_...ible-cystic-8824.html
</a>
"Based on the Phase 2 data announced today, Vertex plans to initiate a combination trial of VX-809 with the CFTR potentiator VX-770 in patients with the most common CFTR mutation, F508del, in the second half of 2010. In in vitro studies, a combination regimen of VX-770 and VX-809 has been shown to increase CFTR activity when compared to dosing of VX-770 or VX-809 as single agents. In addition, Vertex is conducting further analyses of the Phase 2a data and may explore the option to evaluate VX-809 doses of greater than 200 mg when dosed as a single agent".
<a target=_blank class=ftalternatingbarlinklarge href="http://clinicaltrials.gov/ct2/show/NCT00966602
">http://clinicaltrials.gov/ct2/show/NCT00966602
</a>
From an earlier press release, it sounds like later this year
<a target=_blank class=ftalternatingbarlinklarge href="http://www.drugs.com/clinical_trials/vertex-announces-results-phase-2a-trial-vx-809-targeting-defective-protein-responsible-cystic-8824.html
">http://www.drugs.com/clinical_...ible-cystic-8824.html
</a>
"Based on the Phase 2 data announced today, Vertex plans to initiate a combination trial of VX-809 with the CFTR potentiator VX-770 in patients with the most common CFTR mutation, F508del, in the second half of 2010. In in vitro studies, a combination regimen of VX-770 and VX-809 has been shown to increase CFTR activity when compared to dosing of VX-770 or VX-809 as single agents. In addition, Vertex is conducting further analyses of the Phase 2a data and may explore the option to evaluate VX-809 doses of greater than 200 mg when dosed as a single agent".
looks like the interaction study was done
<br /><a target=_blank class=ftalternatingbarlinklarge href="http://clinicaltrials.gov/ct2/show/NCT00966602
">http://clinicaltrials.gov/ct2/show/NCT00966602
</a><br />
<br />From an earlier press release, it sounds like later this year
<br /><a target=_blank class=ftalternatingbarlinklarge href="http://www.drugs.com/clinical_trials/vertex-announces-results-phase-2a-trial-vx-809-targeting-defective-protein-responsible-cystic-8824.html
">http://www.drugs.com/clinical_...ible-cystic-8824.html
</a><br />
<br />"Based on the Phase 2 data announced today, Vertex plans to initiate a combination trial of VX-809 with the CFTR potentiator VX-770 in patients with the most common CFTR mutation, F508del, in the second half of 2010. In in vitro studies, a combination regimen of VX-770 and VX-809 has been shown to increase CFTR activity when compared to dosing of VX-770 or VX-809 as single agents. In addition, Vertex is conducting further analyses of the Phase 2a data and may explore the option to evaluate VX-809 doses of greater than 200 mg when dosed as a single agent".
<br /><a target=_blank class=ftalternatingbarlinklarge href="http://clinicaltrials.gov/ct2/show/NCT00966602
">http://clinicaltrials.gov/ct2/show/NCT00966602
</a><br />
<br />From an earlier press release, it sounds like later this year
<br /><a target=_blank class=ftalternatingbarlinklarge href="http://www.drugs.com/clinical_trials/vertex-announces-results-phase-2a-trial-vx-809-targeting-defective-protein-responsible-cystic-8824.html
">http://www.drugs.com/clinical_...ible-cystic-8824.html
</a><br />
<br />"Based on the Phase 2 data announced today, Vertex plans to initiate a combination trial of VX-809 with the CFTR potentiator VX-770 in patients with the most common CFTR mutation, F508del, in the second half of 2010. In in vitro studies, a combination regimen of VX-770 and VX-809 has been shown to increase CFTR activity when compared to dosing of VX-770 or VX-809 as single agents. In addition, Vertex is conducting further analyses of the Phase 2a data and may explore the option to evaluate VX-809 doses of greater than 200 mg when dosed as a single agent".
Thanks! I think I saw the earlier press release about the end of 2010, but wondered if they had determined when yet. I did notice that in the clinical trial with non CFers, they excluded from the study those who had been treated with either VX 770 or VX 809 before. I guess that means I will probably not be eligible then anyway.
Thanks! I think I saw the earlier press release about the end of 2010, but wondered if they had determined when yet. I did notice that in the clinical trial with non CFers, they excluded from the study those who had been treated with either VX 770 or VX 809 before. I guess that means I will probably not be eligible then anyway.
Thanks! I think I saw the earlier press release about the end of 2010, but wondered if they had determined when yet. I did notice that in the clinical trial with non CFers, they excluded from the study those who had been treated with either VX 770 or VX 809 before. I guess that means I will probably not be eligible then anyway.